ERCC4 and urinary bladder carcinoma: Collectively, these findings indicate that hnRNPK enhances bladder cancer cell anti‐apoptosis and chemoresistance to cisplatin by regulating XAF1 and ERCC4 and that it may be a potential target for drug development.